HeartSciences Inc. (NASDAQ:HSCS) Stock Short Interest Report for October

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 63,146 shares, an increase of 126.1% from the September 30th total of 27,931 shares. Based on an average daily trading volume, of 332,122 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.3% of the company’s shares are short sold.

Analysts Set New Price Targets

Several analysts have recently commented on HSCS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, September 21st. Wall Street Zen upgraded shares of HeartSciences from a “sell” rating to a “hold” rating in a report on Sunday, September 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Trading Down 8.3%

Shares of HSCS traded down $0.30 during trading hours on Friday, reaching $3.31. The stock had a trading volume of 54,480 shares, compared to its average volume of 226,506. The company has a market capitalization of $16.45 million, a price-to-earnings ratio of -1.03 and a beta of 1.76. The firm has a 50-day simple moving average of $3.61 and a 200 day simple moving average of $2.73. HeartSciences has a 12 month low of $1.63 and a 12 month high of $5.25.

HeartSciences (NASDAQ:HSCS) last posted its earnings results on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.10 million. On average, equities analysts forecast that HeartSciences will post -2.99 EPS for the current year.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical technology company focused on improving the detection and assessment of heart disease through advanced electrocardiography (ECG). The company develops diagnostic tools designed to provide clinicians with additional information about cardiac function using a standard, noninvasive ECG test.

Its principal technology is the MyoVista ECG system, which uses the company’s proprietary wavelet-based ECG, or wavECG, technology. MyoVista is designed to assess mechanical aspects of the heart, including left ventricular diastolic function, which may help identify cardiac abnormalities that are not readily detected through conventional ECG analysis.